No statistically significant heterogeneity was observed in PFS and OS analyses.<h4>Discussion and conclusion</h4>This study suggests that one-third of women with advanced or recurrent vulvar cancer may, without the influence of PD-L1 status, benefit from pembrolizumab treatment despite a decline in both PFS and OS at 12 months. The gene discussed is CD274; the disease is vulva cancer.